Pharma BD Deal Intelligence
A mixed bag two years on: Vertex's $100M upfront to CRISPR Therapeutics helped push the unedited VX-880 to positive Phase 3 data in June 2025, but the hypoimmune-adjacent VX-264 device route was discontinued in March 2025 with a roughly $400M impairment.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Vertex Pharmaceuticals is paying CRISPR Therapeutics $100 million upfront and up to $230 million in milestones for access to CRISPR's gene-editing technology…
Vertex Pharmaceuticals and CRISPR Therapeutics have deepened their long-running alliance with a new $330 million licensing pact for gene-editing rights in type…
Vertex Pharmaceuticals and CRISPR Therapeutics have expanded their long-standing partnership with a new licensing deal worth up to $330 million centered on…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Vertex paid CRISPR Therapeutics $100M upfront for non-exclusive rights to CRISPR/Cas9 technology to accelerate development of Vertex's hypoimmune (gene-edited) islet cell therapies for Type 1 diabetes; CRISPR is eligible for up to $230M in R&D milestones plus royalties on future products. The strategic goal is an off-the-shelf islet cell therapy that does not require chronic immunosuppression. Post-deal: Vertex's unedited islet program zimislecel (VX-880), which still requires immunosuppression, advanced to Phase 3 and posted positive 12-month ADA data in June 2025 (full-dose participants achieved insulin independence), with global regulatory submissions guided for 2026. A separate device-based immunosuppression-free route, VX-264 (encapsulated cells, no gene editing), missed its Phase 1/2 efficacy endpoint and was discontinued in March 2025 (~$400M asset impairment). The CRISPR-licensed gene-edited hypoimmune approach -- editing zimislecel-derived cells to cloak them from the immune system -- remains the active, preclinical path to an immunosuppression-free therapy, keeping the deal thesis intact.
2M US cases/yr · $30.0B Global diabetes care market (insulin + CGM, 2023, USD MM) · 330 Total Vertex-CRISPR T1D deal size (USD MM, $100M upfront + $230M milestones)
Type 1 diabetes (T1D) affects approximately 2 million Americans, including roughly 304,000 children and adolescents (CDC National Diabetes Statistics Report 2022). T1D is characterized by autoimmune destruction of pancreatic beta cells, requiring lifelong exogenous insulin and producing substantial morbidity from hypoglycemia, diabetic ketoacidosis, and long-term microvascular and macrovascular complications. The global insulin and continuous glucose monitoring market exceeds $30 billion, dominated by Novo Nordisk, Sanofi, Eli Lilly, Dexcom, Abbott and Medtronic. Vertex's zimislecel (VX-880, now branded as the investigational cell therapy under Phase 1/2/3 FORWARD program) is a stem-cell-derived, fully differentiated allogeneic islet-cell therapy infused into the hepatic portal vein; early clinical data have shown insulin independence in the majority of dosed patients but require chronic immunosuppression, limiting population addressability. The strategic prize for Vertex and CRISPR is hypoimmune (gene-edited) islet cells that would evade allogeneic immune rejection without systemic immunosuppression, broadening eligible T1D population from ~60,000 severe hypoglycemia patients to potentially the full 2 million T1D population. Celltrans' and ViaCyte's (now Vertex-owned) prior programs, plus Sana Biotechnology's UP421 and CRISPR-edited islet work, define the competitive frontier.
The stem-cell-derived islet therapy and hypoimmune cell therapy landscape for T1D features a small group of late-stage leaders and platform partners. Vertex owns the lead clinical program (VX-880/zimislecel, Phase 1/2/3 FORWARD; VX-264 device-encapsulated candidate, Phase 1/2) after acquiring ViaCyte in September 2022 for $320M. Sana Biotechnology (UP421 allogeneic hypoimmune-edited pancreatic islet cells, UP421 Phase 1 data January 2025 showed survival without immunosuppression in T1D patient). CRISPR Therapeutics itself has VCTX211 and VCTX212 hypoimmune programs (the non-exclusive Vertex license allows both companies to develop in parallel). Sigilon Therapeutics (SIG-002, afibromer-encapsulated islet cells; acquired by Lilly June 2023). Semma Therapeutics predecessor (acquired by Vertex 2019). Sernova (Cell Pouch System, Phase 1/2 with U Chicago). Beta-O2 Technologies (βAir device). Broader cell-therapy engineering peers: Poseida Therapeutics, Cellino (automated islet manufacturing), Editas Medicine (gene editing), Intellia Therapeutics (in vivo CRISPR). Vertex's incremental CRISPR license is specifically non-exclusive, reflecting both parties' intent to maintain optionality on editing platforms while Vertex commercializes the end-product cell therapy.
Vertex's encapsulated-cell program VX-264 (a non-gene-edited route to immunosuppression-free therapy) was generally safe but did not deliver C-peptide increases sufficient for benefit; Vertex discontinued it and recorded a ~$400M asset impairment. The gene-edited hypoimmune approach licensed from CRISPR remains the active path to an immunosuppression-free islet therapy.
At the ADA 85th Scientific Sessions Vertex reported full-dose participants achieved insulin independence at 12 months on zimislecel. The unedited program still requires immunosuppression; the CRISPR-licensed gene-edited hypoimmune version of these cells remains preclinical. Vertex guided to global regulatory submissions in 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG (this deal) | 2023 | $330M | — |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
← Browse all deals · How we score deals
More: 2023 deals · Vertex Pharmaceuticals Incorporated deals · Metabolic deals